Benzinga | Feb 22, 2021 05:19AM EST

Zoetis' Solensia Wins European Nod For Osteoarthritis Pain In Cats

* Animal health company Zoetis Inc (NYSE: ZTS) received the European Commission's marketing approval for Solensia (frunevetmab), an injectable monoclonal antibody for the alleviation of pain associated with osteoarthritis in cats.

* Solensia targets Nerve Growth Factor (NGF), a key player in osteoarthritis pain. The veterinarian delivers the treatment as a monthly injection (under the skin).

* In November last year, the Commission approved a similar product, Librela (bedinvetmab), for dogs.

* Price Action: ZTS stock closed 4.7% lower at $160 on Friday.